Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
Capmatinib + Trametinib for Non-Small Cell Lung Cancer
Recruiting3 awardsPhase 1
San Francisco, California
This trial is testing the side effects and best doses of two drugs, capmatinib and trametinib, when given together to treat patients with metastatic non-small cell lung cancer that has a mutation in the MET gene.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.